GeoVax Labs (NASDAQ:GOVX) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report issued on Thursday,Benzinga reports. The firm currently has a $18.00 price objective on the stock.

Several other analysts have also commented on the stock. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research report on Friday, November 15th. Alliance Global Partners started coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price on the stock. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, GeoVax Labs presently has an average rating of “Buy” and an average price target of $14.20.

GeoVax Labs Stock Performance

Shares of GeoVax Labs stock opened at $2.24 on Thursday. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18. The firm’s 50 day simple moving average is $2.47 and its two-hundred day simple moving average is $2.81.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same quarter in the previous year, the company earned ($4.80) EPS. Sell-side analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current year.

Hedge Funds Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC bought a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs at the end of the most recent reporting period. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.